Bayer discusses relevant clinical study results

Conference|EURETINA

Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.


Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.

See more EURETINA coverage here

Related Videos
Related Content

ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301

May 1st 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease

April 27th 2023

ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301

May 1st 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease

April 27th 2023

ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301

May 1st 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease

April 27th 2023
© 2023 MJH Life Sciences

All rights reserved.